

# THE RHEUMATOID DISEASE FOUNDATION

RT. 4, BOX 137, FRANKLIN, TN 37064 / (615) 646-1030

Feb. 24, 1987

Brian M. Susskind, Ph.D.  
Medical College of Virginia  
Box 629 -- MCV Station  
Richmond, VA 23298

Dear Brian:


Thanks for copy of letter to Pybus dated 2/18/87.

My comments on action of metronidazole requiring appropriate micro-flora came from research pharmacologist at Vanderbilt University who conducted some tests for me using tinidazole.

He stated that metronidazole required good intestinal microflora to be metabolized and that such metabolization did not follow from human enzyme systems. This, he said, is contrary to tinidazole and clotrimazole which can follow both chains to reach metabolites.

Further, be it noted in the Neff/Chapdelaine study at Vanderbilt University: Metronidazole in dosages used in vitro against various amoebae showed disappointing action against amoeba, which was not at all true for clotrimazole. Considering that most of these medicines are sometimes anti-amoebic, anti-bacterial, viral-static and anti-viral, one can only assume that in the case of metronidazole it is quite important to know how it does act inside the human body. (See "Chemosensitivity Tests" attached to Neff's study)

Cordially,

  
Perry A. Chapdelaine, Sr.

C: Pybus

## Board Members

### United States

**John M. Baron, D.O.**

*Chairman*

**Frederick H. Binford, M.A.**

*Treasurer*

**Carol Blount, R.N.**

*Member*

**Jack M. Blount, M.D.**

*Chairman Ex Officio*

**Warren B. Causey**

*President*

**Perry A. Chapdelaine, Sr., M.A.**

*Executive Director/Secretary*

**Jim Johnston, C.P.A.**

*Accountant*

**John Kern, C.P.A.**

*Accountant*

**Dr. Paul K. Pybus**

*Chief Medical Advisor*

**Donald Vansant**

*Assistant Treasurer*

**Eugene Wolcott, M.D.**

*Senior Vice Chairman*

### Affiliates

*Australia*

**Terry Crommelin**

*England*

**Kay D. Hitchen**

*South Africa*

**Mrs. L.A. Birnie**

*Physicians And Scientists*

More than 200 (chiefly in U.S.A.),

including **Canada, England, West Germany, Mexico, The Netherlands, Puerto Rico, Republic of South Africa.**

The Rheumatoid Disease Foundation is a project of  
The Roger Wyburn-Mason & Jack M. Blount  
Foundation for the Eradication of Rheumatoid  
Disease, Inc.

Tax Exemption approved by the  
United States Internal Revenue Service

Chartered State of Tennessee